Israel China Biotechnology (ICB) Ltd (ICB) - Net Assets
Based on the latest financial reports, Israel China Biotechnology (ICB) Ltd (ICB) has net assets worth ILA2.55 Million ILA (≈ $6.83K USD) as of June 2021. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA6.66 Million ≈ $17.86K USD) and total liabilities (ILA4.11 Million ≈ $11.02K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Israel China Biotechnology (ICB) Ltd total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA2.55 Million |
| % of Total Assets | 38.26% |
| Annual Growth Rate | -39.45% |
| 5-Year Change | -75.34% |
| 10-Year Change | N/A |
| Growth Volatility | 50.45 |
Israel China Biotechnology (ICB) Ltd - Net Assets Trend (2015–2020)
This chart illustrates how Israel China Biotechnology (ICB) Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Israel China Biotechnology (ICB) Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Israel China Biotechnology (ICB) Ltd (2015–2020)
The table below shows the annual net assets of Israel China Biotechnology (ICB) Ltd from 2015 to 2020. For live valuation and market cap data, see Israel China Biotechnology (ICB) Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | ILA470.00K ≈ $1.26K |
-75.11% |
| 2019-12-31 | ILA1.89 Million ≈ $5.06K |
-74.53% |
| 2018-12-31 | ILA7.41 Million ≈ $19.87K |
+539.42% |
| 2017-12-31 | ILA-1.69 Million ≈ $-4.52K |
-188.51% |
| 2016-12-31 | ILA1.91 Million ≈ $5.11K |
-67.04% |
| 2015-12-31 | ILA5.78 Million ≈ $15.50K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Israel China Biotechnology (ICB) Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2948000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ILA98.36 Million | 20928.51% |
| Total Equity | ILA470.00K | 100.00% |
Israel China Biotechnology (ICB) Ltd Competitors by Market Cap
The table below lists competitors of Israel China Biotechnology (ICB) Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
edding AG
F:EDD3
|
$19.47 Million |
|
Premium Catering (Holdings) Limited
NASDAQ:PC
|
$19.48 Million |
|
Fabrity Holding S.A.
WAR:FAB
|
$19.51 Million |
|
Elve S.A
AT:ELBE
|
$19.51 Million |
|
LANCOR HOLDINGS LTD.
NSE:LANCORHOL
|
$19.46 Million |
|
Cyngn Inc
NASDAQ:CYN
|
$19.46 Million |
|
NEVADA LITHIUM RESOURCES
F:87K
|
$19.45 Million |
|
People's Garment Public Company Limited
BK:PG
|
$19.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Israel China Biotechnology (ICB) Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from 1,888,000 to 470,000, a change of -1,418,000 (-75.1%).
- Net loss of 11,932,000 reduced equity.
- Other factors increased equity by 10,514,000.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-11.93 Million | -2538.72% |
| Other Changes | ILA10.51 Million | +2237.02% |
| Total Change | ILA- | -75.11% |
Book Value vs Market Value Analysis
This analysis compares Israel China Biotechnology (ICB) Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 187305.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ILA-0.12 | ILA2349.00 | x |
| 2018-12-31 | ILA0.51 | ILA2349.00 | x |
| 2019-12-31 | ILA0.07 | ILA2349.00 | x |
| 2020-12-31 | ILA0.01 | ILA2349.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Israel China Biotechnology (ICB) Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2538.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14375.90%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 17.75x
- Recent ROE (-2538.72%) is below the historical average (-534.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -75.53% | -2386.89% | 0.02x | 1.41x | ILA-4.95 Million |
| 2016 | -202.26% | -4015.63% | 0.02x | 2.13x | ILA-4.05 Million |
| 2017 | 0.00% | -5723.44% | 0.05x | 0.00x | ILA-3.49 Million |
| 2018 | -48.87% | -3450.48% | 0.01x | 1.33x | ILA-4.36 Million |
| 2019 | -339.35% | -4609.35% | 0.01x | 6.13x | ILA-6.60 Million |
| 2020 | -2538.72% | -14375.90% | 0.01x | 17.75x | ILA-11.98 Million |
Industry Comparison
This section compares Israel China Biotechnology (ICB) Ltd's net assets metrics with peer companies in the Investment Banking & Investment Services industry.
Industry Context
- Industry: Investment Banking & Investment Services
- Average net assets among peers: $191,480,333
- Average return on equity (ROE) among peers: -35.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Israel China Biotechnology (ICB) Ltd (ICB) | ILA2.55 Million | -75.53% | 1.61x | $19.47 Million |
| Inbar Group Finance Ltd (INBR) | $13.25 Million | -129.81% | 4.17x | $19.95 Million |
| Meitav Dash Investments Ltd (MTDS) | $430.32 Million | 15.28% | 1.01x | $1.09 Billion |
| Poalim Ibi (PIU) | $130.87 Million | 7.79% | 0.05x | $108.63 Million |
About Israel China Biotechnology (ICB) Ltd
Silver Castle Holdings Ltd operates as a healthcare investment company. It invests in companies in the biomedical field in Israel. The company was formerly known as Israel China Biotechnology (ICB) Ltd and changed its name to Silver Castle Holdings Ltd in February 2022. Silver Castle Holdings Ltd was founded in 2000 and is based in Tel Aviv, Israel.